<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505190</url>
  </required_header>
  <id_info>
    <org_study_id>YP39432</org_study_id>
    <nct_id>NCT03505190</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.</brief_title>
  <official_title>A Randomized, Sponsor-Open, Investigator-Blind, Subject-Blind, Placebo-Controlled, Single Ascending Dose, to Investigate the Safety, Tolerability and Pharmacokinetics of RO7062931 Following Subcutaneously Administration in Healthy Chinese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study will evaluate the safety, tolerability and pharmacokinetics of single&#xD;
      ascending subcutaneously administered doses of RO7062931 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Actual">July 5, 2019</completion_date>
  <primary_completion_date type="Actual">July 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events and AEs of Special Interest</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Adverse events of special interest for this study include the following:&#xD;
Cases of an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice&#xD;
Suspected transmission of an infectious agent by the study drug&#xD;
Severe injection site reactions&#xD;
Renal adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Marked Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation and Urinalysis Test Results</measure>
    <time_frame>Baseline, Day 2, 8, 15, 29, 85</time_frame>
    <description>Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Baseline; pre-dose, 1 hour (h), 4, 8, 12h post-dose Day 1, 24h post-dose Day 2, 8, 15, 29, 85</time_frame>
    <description>Table entries provide the percentage of Participants with a during treatment assessment abnormality in the direction specified regardless of this abnormality at baseline. Abnormalities reported in Participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With T-wave Abnormalities</measure>
    <time_frame>Baseline; pre-dose, 1 hour (h), 4, 8, 12h post-dose Day 1, 24h post-dose Day 2, 8, 15, 29, 85</time_frame>
    <description>Table entries provide the percentage of Participants with a during treatment assessment abnormality in the direction specified regardless of this abnormality at baseline. Abnormalities reported in Participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With U-wave Abnormalities</measure>
    <time_frame>Baseline; pre-dose, 1 hour (h), 4, 8, 12h post-dose Day 1, 24h post-dose Day 2, 8, 15, 29, 85</time_frame>
    <description>Table entries provide the percentage of Participants with a during treatment assessment abnormality in the direction specified regardless of this abnormality at baseline. Abnormalities reported in Participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
    <description>Observed Maximum Plasma Concentration were obtained after the participants received the RO7062931</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
    <description>Time to reach the observed Maximum Plasma Concentration were obtained after the participants received the RO7062931.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
    <description>Area Under the Plasma Concentration-time Curve Extrapolated to infinity was calculated based on Non-Compartment Analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Quantifiable Time-Point (AUC0-last) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
    <description>Area Under the Plasma Concentration-time Curve up to the last measurable concentration was calculated based on Non-Compartment Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
    <description>Terminal Half-life was calculated based on Non-Compartment Analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
    <description>Apparent oral clearance was calculated from Dose/AUCinf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
    <description>Apparent volume of distribution was calculated from Dose/AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount of RO7062931 Excreted in Urine (Ae)</measure>
    <time_frame>(0-4), (4-8), (8-12), (12-24)h post-dose Day 1</time_frame>
    <description>Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Cumulative Amount of RO7062931 Excreted in the Urine Over Total Dose (Fe)</measure>
    <time_frame>0-24h h post-dose Day 1</time_frame>
    <description>The fraction of cumulative amount in urine were calculated based on Ae/Dose</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>RO7062931 0.3mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7062931 1.0mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7062931 2.0mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7062931 4.0mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7062931</intervention_name>
    <description>RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.</description>
    <arm_group_label>RO7062931 0.3mg/kg</arm_group_label>
    <arm_group_label>RO7062931 1.0mg/kg</arm_group_label>
    <arm_group_label>RO7062931 2.0mg/kg</arm_group_label>
    <arm_group_label>RO7062931 4.0mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered subcutaneously (SC).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>RO7062931 0.3mg/kg</arm_group_label>
    <arm_group_label>RO7062931 1.0mg/kg</arm_group_label>
    <arm_group_label>RO7062931 2.0mg/kg</arm_group_label>
    <arm_group_label>RO7062931 4.0mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chinese healthy male and female (of non-childbearing potential) volunteers.&#xD;
&#xD;
          -  A Body Mass Index (BMI) between 19 to 27 kilogram per square meter (kg/m2) inclusive&#xD;
             and a body weight of at least 45 kg.&#xD;
&#xD;
          -  Women should be of non-childbearing potential. These include those who have undergone&#xD;
             surgical sterilization (removal of ovaries and/or uterus) or are post-menopausal.&#xD;
&#xD;
          -  Men must agree to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures during treatment and up to 105 days after the last dose of&#xD;
             RO7062931, and agree to refrain from donating sperm during this same period.&#xD;
&#xD;
          -  Non-smoker (nor tobacco containing products) for at least 90 days prior to dosing on&#xD;
             Day 1 and agree to remain as non-smoker during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of drug or alcohol abuse or dependence in previous 6 months.&#xD;
&#xD;
          -  Positive urine drug and alcohol screen or positive cotinine test at Screening or Day&#xD;
             -1.&#xD;
&#xD;
          -  Positive result on hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency&#xD;
             virus (HIV)-1 and -2 at Screening.&#xD;
&#xD;
          -  Confirmed blood pressure or resting pulse rate outside of accepted ranges.&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 90 days prior to&#xD;
             screening.&#xD;
&#xD;
          -  Donation of blood over 500 milliliters (mL) within three months prior to screening.&#xD;
&#xD;
          -  Any major illness within the one month, or any febrile illness within two weeks&#xD;
             preceding the screening visit.&#xD;
&#xD;
          -  Alcohol consumption of more than 2 standard drinks per day on average.&#xD;
&#xD;
          -  Screening or baseline ECG evidence of atrial fibrillation, atrial flutter, complete&#xD;
             right or left bundle branch block, Wolff-Parkinson-White syndrome, or cardiac&#xD;
             pacemaker.&#xD;
&#xD;
          -  Any out of range findings in liver function tests, INR and renal function tests or any&#xD;
             clinically significant abnormalities (as judged by the Investigator) in the physical&#xD;
             examination and in the remaining laboratory test results (including hepatic and renal&#xD;
             panels, complete blood count, chemistry panel and urinalysis) at Screening or on&#xD;
             Day-1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <results_first_submitted>June 10, 2020</results_first_submitted>
  <results_first_submitted_qc>July 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2020</results_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03505190/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Planned: Up to 50 healthy volunteers (HVs) across 5 cohorts of 10 HVs (8 active, 2 placebo) per dose-level.&#xD;
Actual: A total of 41 HVs were enrolled across 4 dose cohorts.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RO7062931 0.3mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="P2">
          <title>RO7062931 1.0mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="P3">
          <title>RO7062931 2.0mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="P4">
          <title>RO7062931 4.0mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Participants will receive matching placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RO7062931 0.3mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="B2">
          <title>RO7062931 1.0mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="B3">
          <title>RO7062931 2.0mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="B4">
          <title>RO7062931 4.0mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Participants will receive matching placebo.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="6.4"/>
                    <measurement group_id="B2" value="29.3" spread="11.5"/>
                    <measurement group_id="B3" value="29.8" spread="11.0"/>
                    <measurement group_id="B4" value="29.6" spread="9.2"/>
                    <measurement group_id="B5" value="34.5" spread="15."/>
                    <measurement group_id="B6" value="30.2" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian/ Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events and AEs of Special Interest</title>
        <description>Adverse events of special interest for this study include the following:&#xD;
Cases of an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice&#xD;
Suspected transmission of an infectious agent by the study drug&#xD;
Severe injection site reactions&#xD;
Renal adverse events</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events and AEs of Special Interest</title>
          <description>Adverse events of special interest for this study include the following:&#xD;
Cases of an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice&#xD;
Suspected transmission of an infectious agent by the study drug&#xD;
Severe injection site reactions&#xD;
Renal adverse events</description>
          <population>The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="62.5"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events of Special interest (AESI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Marked Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation and Urinalysis Test Results</title>
        <description>Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.</description>
        <time_frame>Baseline, Day 2, 8, 15, 29, 85</time_frame>
        <population>The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Marked Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation and Urinalysis Test Results</title>
          <description>Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.</description>
          <population>The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SGOT/AST High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Total, Abs, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Electrocardiogram (ECG) Abnormalities</title>
        <description>Table entries provide the percentage of Participants with a during treatment assessment abnormality in the direction specified regardless of this abnormality at baseline. Abnormalities reported in Participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
        <time_frame>Baseline; pre-dose, 1 hour (h), 4, 8, 12h post-dose Day 1, 24h post-dose Day 2, 8, 15, 29, 85</time_frame>
        <population>The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Electrocardiogram (ECG) Abnormalities</title>
          <description>Table entries provide the percentage of Participants with a during treatment assessment abnormality in the direction specified regardless of this abnormality at baseline. Abnormalities reported in Participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
          <population>The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Duration Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Duration High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Duration Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Duration High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF - Fridericia's Correction Formula Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF - Fridericia's Correction Formula High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) for RO7062931</title>
        <description>Observed Maximum Plasma Concentration were obtained after the participants received the RO7062931</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
        <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) for RO7062931</title>
          <description>Observed Maximum Plasma Concentration were obtained after the participants received the RO7062931</description>
          <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.71" spread="39.5"/>
                    <measurement group_id="O2" value="57.09" spread="28.8"/>
                    <measurement group_id="O3" value="113.52" spread="40.3"/>
                    <measurement group_id="O4" value="299.39" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) for RO7062931</title>
        <description>Time to reach the observed Maximum Plasma Concentration were obtained after the participants received the RO7062931.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
        <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) for RO7062931</title>
          <description>Time to reach the observed Maximum Plasma Concentration were obtained after the participants received the RO7062931.</description>
          <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.38" lower_limit="1.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="2.87" lower_limit="1.9" upper_limit="3.9"/>
                    <measurement group_id="O4" value="2.85" lower_limit="1.4" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) for RO7062931</title>
        <description>Area Under the Plasma Concentration-time Curve Extrapolated to infinity was calculated based on Non-Compartment Analysis.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
        <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) for RO7062931</title>
          <description>Area Under the Plasma Concentration-time Curve Extrapolated to infinity was calculated based on Non-Compartment Analysis.</description>
          <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.26" spread="9.0"/>
                    <measurement group_id="O2" value="349.75" spread="14.8"/>
                    <measurement group_id="O3" value="791.99" spread="19.9"/>
                    <measurement group_id="O4" value="2180.74" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Quantifiable Time-Point (AUC0-last) for RO7062931</title>
        <description>Area Under the Plasma Concentration-time Curve up to the last measurable concentration was calculated based on Non-Compartment Analysis</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
        <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Quantifiable Time-Point (AUC0-last) for RO7062931</title>
          <description>Area Under the Plasma Concentration-time Curve up to the last measurable concentration was calculated based on Non-Compartment Analysis</description>
          <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.16" spread="9.0"/>
                    <measurement group_id="O2" value="348.33" spread="14.8"/>
                    <measurement group_id="O3" value="786.33" spread="20.8"/>
                    <measurement group_id="O4" value="2114.90" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life (t1/2) for RO7062931</title>
        <description>Terminal Half-life was calculated based on Non-Compartment Analysis.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
        <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life (t1/2) for RO7062931</title>
          <description>Terminal Half-life was calculated based on Non-Compartment Analysis.</description>
          <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="44.6"/>
                    <measurement group_id="O2" value="66.59" spread="38.6"/>
                    <measurement group_id="O3" value="81.83" spread="24.0"/>
                    <measurement group_id="O4" value="88.78" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F) for RO7062931</title>
        <description>Apparent oral clearance was calculated from Dose/AUCinf.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
        <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) for RO7062931</title>
          <description>Apparent oral clearance was calculated from Dose/AUCinf.</description>
          <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.24" spread="11.4"/>
                    <measurement group_id="O2" value="27.23" spread="18.8"/>
                    <measurement group_id="O3" value="25.24" spread="18.5"/>
                    <measurement group_id="O4" value="17.46" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) for RO7062931</title>
        <description>Apparent volume of distribution was calculated from Dose/AUCinf</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
        <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) for RO7062931</title>
          <description>Apparent volume of distribution was calculated from Dose/AUCinf</description>
          <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.27" spread="45.7"/>
                    <measurement group_id="O2" value="2616.31" spread="35.8"/>
                    <measurement group_id="O3" value="2980.22" spread="40.0"/>
                    <measurement group_id="O4" value="2235.97" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amount of RO7062931 Excreted in Urine (Ae)</title>
        <description>Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.</description>
        <time_frame>(0-4), (4-8), (8-12), (12-24)h post-dose Day 1</time_frame>
        <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amount of RO7062931 Excreted in Urine (Ae)</title>
          <description>Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.</description>
          <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ae 0-8h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.35" spread="6.64"/>
                    <measurement group_id="O2" value="133.79" spread="29.09"/>
                    <measurement group_id="O3" value="326.90" spread="106.77"/>
                    <measurement group_id="O4" value="1433.92" spread="595.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae 0-24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.88" spread="6.69"/>
                    <measurement group_id="O2" value="147.88" spread="40.78"/>
                    <measurement group_id="O3" value="545.61" spread="139.56"/>
                    <measurement group_id="O4" value="1977.71" spread="513.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Cumulative Amount of RO7062931 Excreted in the Urine Over Total Dose (Fe)</title>
        <description>The fraction of cumulative amount in urine were calculated based on Ae/Dose</description>
        <time_frame>0-24h h post-dose Day 1</time_frame>
        <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Cumulative Amount of RO7062931 Excreted in the Urine Over Total Dose (Fe)</title>
          <description>The fraction of cumulative amount in urine were calculated based on Ae/Dose</description>
          <population>The PK analysis population included all healthy volunteers randomized and adherent to the protocol. Participants were excluded if they significantly violated the inclusion/exclusion criteria, deviated significantly from the protocol or if data were unavailable or incomplete. Data presented is only for participants included in the actual analysis.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.20"/>
                    <measurement group_id="O2" value="1.63" spread="0.30"/>
                    <measurement group_id="O3" value="2.79" spread="0.72"/>
                    <measurement group_id="O4" value="5.26" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With T-wave Abnormalities</title>
        <description>Table entries provide the percentage of Participants with a during treatment assessment abnormality in the direction specified regardless of this abnormality at baseline. Abnormalities reported in Participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
        <time_frame>Baseline; pre-dose, 1 hour (h), 4, 8, 12h post-dose Day 1, 24h post-dose Day 2, 8, 15, 29, 85</time_frame>
        <population>The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With T-wave Abnormalities</title>
          <description>Table entries provide the percentage of Participants with a during treatment assessment abnormality in the direction specified regardless of this abnormality at baseline. Abnormalities reported in Participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
          <population>The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 1H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 4H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 8H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 12H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 / 24H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 / 168H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Visit Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Visit Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Visit Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With U-wave Abnormalities</title>
        <description>Table entries provide the percentage of Participants with a during treatment assessment abnormality in the direction specified regardless of this abnormality at baseline. Abnormalities reported in Participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
        <time_frame>Baseline; pre-dose, 1 hour (h), 4, 8, 12h post-dose Day 1, 24h post-dose Day 2, 8, 15, 29, 85</time_frame>
        <population>The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>RO7062931 0.3mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>RO7062931 1.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>RO7062931 2.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>RO7062931 4.0mg/kg</title>
            <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants will receive matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With U-wave Abnormalities</title>
          <description>Table entries provide the percentage of Participants with a during treatment assessment abnormality in the direction specified regardless of this abnormality at baseline. Abnormalities reported in Participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
          <population>The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 1H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 4H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 8H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 12H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 / 24H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 / 168H</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Visit Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="12.5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Visit Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Visit Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="12.5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 14 months</time_frame>
      <desc>Number of events includes all occurrences. The Safety Population includes all participants who received study drug or placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>RO7062931 0.3mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="E2">
          <title>RO7062931 1.0mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="E3">
          <title>RO7062931 2.0mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="E4">
          <title>RO7062931 4.0mg/kg</title>
          <description>Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Participants will receive matching placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Noninfective gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tongue cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

